In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

Published Date: 04 Jun 2024

In this context, the second belantamab mafodotin-containing triplet to demonstrate potency.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survivors of childhood brain cancer are more likely to be held back in school

2.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

3.

Research uncovers hidden Australian skin cancer epidemic

4.

In 18 States, alcohol exclusion laws are still in effect.

5.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot